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expandedMSCs derived frommultiple donors are lacking. The objective
of this study is to identify such prognostic markers.
Methods: In this study 20 human MSC donors were tested for their
ability to produce cartilage in a standard chondrogenic differentiation
assay consisting of pellet culture in the presence of serum free medium
and TGFb. Cartilage formation was scored on the basis of histological
matrix formation, mRNA expression levels of chondrogenic marker
genes and quantiﬁcation of glycosaminoglycan deposition. Of each of
these donors genome wide mRNA expression proﬁles were obtained
using an affymetrix microarray platform before the onset of differen-
tiation. In addition, small nucleotide RNAs were isolated for miRNA
proﬁling using a panel of miRNAs previously implemented in
chondrogenesis.
Results: Only 3 donors out of 20 were identiﬁed as donors with high
chondrogenic potential, whereas 9 showed moderate and 8 low chon-
drogenic potential. Despite these huge differences in chondrogenic
potential, genome wide mRNA proﬁling at the onset of differentiation
showed only marginal differences between the 3 groups. In contrast,
proﬁling of microRNAs (miRNAs) previously implemented in chondro-
genesis and cartilage homeostasis showed a very distinctive pattern
between good and bad performing donors. We also studied the changes
in miRNA expression during a 7 day differentiation period of MSCs in
pellet culture and identiﬁedmiR-210 andmiR-630 as positive regulators
of chondrogenesis with miR-630 as a potential marker for high per-
forming donors. In contrast miR-181 and miR-34a, both of which are
negative regulators of chondrogenesis, were up-regulated during
differentiation in bad performing donors.
Conclusions: In contrast to themarginal differences at the global mRNA
level between good and bad MSC donors with respect of chondrogenic
differentiation potential, screening of a panel of miRNAs previously
implemented in cartilage formation showed more clear segregation
between good and bad performing donors. MiRNA proﬁling of MSC
donors may, therefore, have prognostic value to select MSC donors with
respect of their chondrogenic differentiation potential and their
capacity to restore cartilage homeostasis after intra-articular injection
in the osteoarthritic joint.47
THE REPAIR OF FOCAL CARTILAGE DEFECTS USING HUMAN
EMBRYONIC STEM CELLS
A. Cheng, T. Hardingham, S. Kimber. Univ. of Manchester, Manchester,
United Kingdom
Purpose: Damage to articular cartilage occurs frequently as a result of
joint trauma and disease. Cell based treatments to repair defects have
been developed using autologous chondrocytes and bone marrow stem
cells and have shown some success.We have investigated the potential of
human embryonic stem cells (hESC) as a source of chondrocytes, as they
have capacity for unlimited self-renewal and could provide a ready supply
of donor cells. In initialworkwe developed a 14 day culture protocol using
serum free, chemically deﬁned medium and generated chondro-
progenitors from hESC, which were up to 97% SOX9 positive, expressing
COL2A1 and ACAN genes. This system is chemically deﬁned and scalable
and with potential to provide cells for clinical grade use. In this study we
developed the protocol further and tested hESC derived chondro-
progenitors in vivo in focal defects in immunocompromised nude rats.
Methods: Human embryonic stem cells (hESC) expanded on feeder
culturewere transferred to feeder free/ serum free culture on ﬁbronectin
coated plates. After two passages a 14 day chondrogenesis protocol was
initiatedwith a sequential series of growth factors,whichdrive thehESCs
through mesendoderm/mesoderm to chondroprogenitors. These cells
were characterised by qRT-PCR using a range of chondrocyte speciﬁc
marker genes, negative controls and by immunoﬂuorescence for SOX9,
a chondrocyte transcription factor. Some chondro-progenitors were also
derived from hESC transduced with GFP using lentiviral vectors. To test
their capacity for cartilage formation, chondro-progenitors in ﬁbrin gel
(3X106 cells/ml) were implanted into osteochondral defects (2mm
diameter, 2mm deep, 14 defects in 8 animals) in the patella groove of
nude rats. Joint tissue was removed, decalciﬁed, ﬁxed and sectioned for
histological and immunochemical analysis after 4 weeks or 12 weeks.
Results: The hESC derived chondro-progenitors at the end of the
protocol formed cell clusters and showed chondrocyte properties,
including high expression of SOX9. They strongly immunostained forSOX9 protein and for collagen II and for aggrecan and expressed
collagen II and XI genes, but not collagen I and negligible collagen X,
which is a marker for hypertrophic chondrocytes. The expression of
matrilin 3 increased and was more than 50 time higher than matrilin 1
at the end of the protocol, again suggesting an articular rather than an
epiphyseal phenotype. Also, we found the expression of core band
factor beta (CBF-beta) was elevated and ZNF145, ZNF219, p300 and
SirT1 were also increased. Defects in nude rat joints were seeded with
chondro-progenitors (approx 2 x105cells per defect) in ﬁbrin gel and in
a contralateral control, ﬁbrin gel alone. Joint tissue was isolated at 4
weeks and 12 weeks and in these preliminary experiments histology
showed evidence of repair cartilage ﬁlling in the defect areas in the cell
seeded joints (cartilage in 2 from 3 animals at 4 weeks and in 2 from 4
animals at 12 weeks). When GFP cells were implanted they were
detected by ﬂuorescence within areas of neo-cartilage formation and
immunohistology using anti human vimentin antibody conﬁrmed
human cells in the repair tissue, which stained with safranin O for
proteoglycan and immunostained for collagen II. Only ﬁbrous tissuewas
found in the defect areas of joints implanted with ﬁbrin gel only.
Conclusions: Human embryonic stem cells in feeder free, serum free,
chemically deﬁned medium were differentiated into chondrogenic
cells, which when implanted in focal defects in nude rats participated in
the formation of cartilage repair tissue assessed up to 12 weeks. The
study demonstrates that human embryonic stem cells can be efﬁciently
differentiated to produce chondro-progenitors with a protocol that is
suitable for future clinical applications.
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DISEASE MODIFYING, RECEPTOR SELECTIVE ANALOGS OF FGF18 FOR
GLOBAL, ARTICULAR CARTILAGE PRESERVATION AND REPAIR IN
EXPERIMENTAL OSTEOARTHRITIS
A. Yayon y, D. Strauss-Ayali y, E. Rom y, K. Mevorat Kaplan y, L. Niv y, A.
Blom z, W. van den Berg z. y Procore, Nes Ziona, Israel; zRadboud Univ.,
Nijmegen, Netherlands
Purpose: We aimed to study the beneﬁts and potential adverse effects
of FGF18 and FGF18 analogs on joint articular cartilage preservation in
an experimental model for Osteoarthritis (OA).
Methods: A series of genetically engineered isoforms of FGF18, a major
cartilage growth and differentiation factor, were tested in a murine
model for surgically induced Osteoarthritis. OA was induced by trans-
section of the anterior medial meniscotibial ligament in the knee joint,
which causes destabilization. Ligands were selected for their FGF
receptor speciﬁcity, discriminating FGFR2 from FGFR3 signaling in bone
and cartilage. Stabilization and controlled release of the growth factors
were achieved through chemical conjugation to Hyaluronic acid (HA)
which were further enhanced using a novel Fibrin-HA based hydrogel.
Ligands were administered by repeated intra-articular injections into
the murine knee joints according to various regimens.
Results: The capacity of these factors in the preservation and tissue
repair of the various articular cartilage compartments was evident by
histologyand grossmorphology.HA link enhanced thepotency of FGF18.
However, wild type FGF18, particularly when administered as soluble,
free ligand, signiﬁcantly enhanced osteophyte formation and size at all
doses tested. The soluble FGFR3 selective ligand, on the other hand, did
not induce osteophytes formation. Unexpectedly, the Fibrin-HA hydro-
gel by itself conferred a protective effect against damage induced OA.
Conclusions: Our results demonstrate a differential effect of FGF18
analogsdifferent in their FGFreceptoractivationoncartilagepreservation
and remodeling in a murine model of damage induced OA. More specif-
ically we suggest that FGF18 signaling via FGFR2 may be the primary
trigger for enhanced local osteogenic effect and osteophyte formation.49
LOCATION-INDEPENDANT ANALYSIS OF INTRAARTICULAR
SPRIFERMIN EFFECTS ON CARTILAGE STRUCTURE USING ORDERED
VALUES
S. Hellot y, W. Wirth z,x, A. Guermazi {,k, C. Pena Rossi y, F.
Eckstein z,x. yMerck Serono S.A. – Geneva (an afﬁliate of Merck KGaA,
Darmstadt, Germany), Geneva, Switzerland; z Paracelsus Med. Univ.,
Salzburg, Austria; xChondrometrics GmbH, Ainring, Germany; kBoston
Univ., Boston, MA, USA; {Boston Imaging Core Lab (BICL) LLC, Boston,
MA, USA
Abstracts / Osteoarthritis and Cartilage 21 (2013) S9–S62 S33Purpose: There is a high unmet medical need for disease modifying
drugs in OA that have an effect on joint structure. Fibroblast growth
factor 18 (FGF18) promotes chondrocyte proliferation and stabilizes an
anabolic chondrocyte phenotype. Data from a proof-of-concept trial in
knee OA demonstrated that sprifermin (rhFGF18) increased total
cartilage volume and thickness. This effect seemed to be more
pronounced in the lateral compartment, raising the question of the
distribution of the effect on cartilage change on different knee subre-
gions. Here we use a location-independent analysis method, to identify
whether sprifermin modiﬁes the magnitude of (subregional) cartilage
loss compared with placebo, independent of the location where it
occurs in individual joints.
Methods: Study participants (n¼168; 40-year-old; 69% female) had
symptomatic and radiographic femorotibial OA (KLG2 or 3), and were
not conﬁned to medial disease. Sprifermin (10, 30, or 100mg) or placebo
were injected once weekly for 3 weeks after randomization, and at 13
weeks. 1.5mm coronal SPGR MRIs were acquired at baseline and 13, 26
and 52 weeks. Medial (MFTC) and lateral femorotibial cartilage (LFTC)
was segmented by 7 readers, with blinding to acquisition order and
treatment (Chondrometrics GmbH). Cartilage thickness (changes) were
computed in each of 16 femorotibial subregions (5 medial and 5 lateral
tibial, 3 medial and 3 lateral femoral).The location-independent
magnitude of subregional thickness changes (in mm) was calculated
using ordered values (OV), individually assigning the magnitude of
cartilage loss in the subregion with the greatest loss to OV1, the one
with the second greatest loss to OV2, and so forth, and the one with the
smallest loss/greatest increase to OV16). In the current analysis, results
of the 100mg cohort (n¼63) vs. matching placebo (n¼21) were
compared using t-tests.
Results: Total femorotibial cartilage thickness loss at 52 weeks was less
in sprifermin treated than in placebo treated knees, with effects being
signiﬁcant in LFTC (p¼0.03) but not MFTC (p¼0.16) (Table 1). Signiﬁcant
treatment effects (p<0.05) were detected in 2/16 subregions (minimal
p-value ¼0.006 in the external lateral femur), and in 10/16 OVs
(minimal p¼0.004 in OV12). The 10 OVs included some in which
cartilage loss was observed (OV4-8) and some in which cartilage
thickening was observed in the placebo group (OV11-15).
Conclusions: This location-independent analysis shows that sprifermin
can modify the magnitude of cartilage loss in subregions with low OVs,
where (individual) mechanical challenges may be greater and drug
effects may be more important clinically. The OV approach also has the
advantage that no single region must be deﬁned a priori as structural
endpoint, which is challenging given spatial inter-subject heterogeneity
of (subregional) cartilage loss in OA, particularly in cohorts without
predeﬁned (medial or lateral) involvement. The results further show
that OVs are more effective and informative in revealing structural
treatment effects than region-based analysis, and that sprifermin not
only increases cartilage thickness (in regions where no loss is observed),
but actually reduces cartilage loss (in regions where cartilage loss is
observed with placebo).Table 1
Cartilage thickness change (mm) in sprifermin treated vs. placebo knees
Placebo
Mean  SD change
100mg dose




MFTC -0.07  0.18 0.00  0.16 0.43 0.1603
LFTC -0.04  0.19 0.04  0.12 0.58 0.0323
SRmax -0.03  0.11 0.04  0.09 0.78 0.0055
OV1 -0.22  0.16 -0.18  0.15 0.25 0.3529
OV2 -0.15  0.12 -0.12  0.12 0.25 0.3500
OV3 -0.12  0.09 -0.09  0.09 0.39 0.1571
OV4 -0.10  0.08 -0.05  0.07 0.64 0.0198
OV5 -0.08  0.07 -0.04  0.06 0.73 0.0094
OV6 -0.07  0.06 -0.02  0.06 0.79 0.0057
OV7 -0.05  0.06 -0.01  0.06 0.69 0.0132
OV8 -0.03  0.06 0.01  0.05 0.62 0.0244
OV9 -0.01  0.06 0.02  0.05 0.50 0.0708
OV10 0.01  0.06 0.03  0.05 0.49 0.0739
OV11 0.02  0.06 0.05  0.05 0.64 0.0210
OV12 0.03  0.07 0.06  0.04 0.80 0.0044
OV13 0.04  0.06 0.08  0.05 0.78 0.0065
OV14 0.07  0.07 0.10  0.05 0.64 0.0232
OV15 0.09  0.07 0.13  0.06 0.60 0.0305
OV16 0.15  0.10 0.18  0.07 0.35 0.212450
MALALIGNMENT; A POSSIBLE TARGET FOR PREVENTION OF
INCIDENT KNEE OA IN MIDDLE-AGED OVERWEIGHT AND OBESE
WOMEN
J. Runhaar y, M. van Middelkoop y, M. Reijman y, D. Vroegindeweij z, E.H.
Oei y, S.M. Bierma-Zeinstra y. y Erasmus MC, Rotterdam, Netherlands;
zMaasstad Hosp., Rotterdam, Netherlands
Purpose: The present study evaluates the effects of malalignment and
its interaction with BMI on the onset of clinical and radiographic knee
osteoarthritis (OA) over a 2.5 year follow-up period in a high risk group
of middle-aged overweight and obese women.
Methods: Data of the PROOF study (ISRCTN 42823086) were used. In
total, 407 women between 50 and 60 years, with a BMI 27 kg/m2, and
without clinical and radiological knee OA at baseline were included in
this study. Both knees of all 351 women (86%) with baseline knee
alignment data and the primary outcome available were selected. At
baseline, body weight and height were measured and standardized
semi-ﬂexed PA radiographs of both knees were taken according to the
MTP protocol. All subjects ﬁlled in a questionnaire with questions on
knee complaints and number of days with knee pain. All measurements
were repeated after 2.5 years of follow-up. Minimal joint space width
(medial and lateral), K&L grade and anatomical knee alignment angle
were digitally assessed on all radiographs. Varus alignment was deﬁned
as an anatomical angle 184. The predeﬁned primary outcome measure
was the incidence of knee OA, deﬁned as onset of K&L 2 or the onset of
clinical knee OA (according to the ACR criteria), or joint space narrowing
(JSN) 1.0 mm in themedial or lateral compartment. Using Generalized
Estimated Equations, which takes into account the correlation between
knees within subjects, effects of varus and valgus alignment on the
primary outcome and on the items separately were evaluated, with
neutrally aligned knees serving as reference. The interaction between
malalignment and baseline BMI was also studied, by adding BMI and
the interaction term with malalignment to the analysis. If a signiﬁcant
interactionwas found, overweight (BMI< 30 kg/m2) and obese subjects
(BMI  30 kg/m2) were analysed separately. All analyses were adjusted
for K&L grade at baseline and the randomized groups of the interven-
tions of the PROOF study.
Results: Varus alignment was found in 40% and valgus alignment in 13%
of all knees. Baseline characteristics are presented in Table 1. Overall,
only varus alignment had a signiﬁcant effect on the incidence of K&L 2
(9% vs. 3% in neutral knees. OR 2.8, 95% CI 1.3 - 5.9). For the primary
outcome and for medial JSN a signiﬁcant interaction between mala-
lignment and baseline BMI was found (p < 0.01). In obese subjects,
varus alignment had a signiﬁcant effect on the primary outcome (22%
vs. 13% in neutral knees. OR 1.8, 95% CI 1.1 - 3.1) and on medial JSN (9%
vs. 4% in neutral knees. OR 2.6, 95% CI 1.1 - 6.3). These associations were
not found in non-obese subjects.
Conclusions: In women at high risk for developing knee OA, varus
aligned knees had a signiﬁcant increased risk for the development of
radiographickneeOA.Withinobesewomen, varus alignedknees alsohad
a signiﬁcantly increased risk for incidence of knee OA according to the
primary outcome and for joint space narrowing in the medial compart-
ment. Since varus alignment is a potentially modiﬁable factor, results
from the present study suggest that varus alignmentmight be a target for
the prevention of knee OA inmiddle-aged overweight and obesewomen.51
DOES CARTILAGE THICKNESS CHANGE DIFFER BETWEEN ACL
DEFICIENT KNEES WITH ANDWITHOUT RECONSTRUCTION SURGERY
W. Wirth y, F. Eckstein y, M. Hudelmaier y, S. Lohmander z, R.
Frobell z. y Paracelsus Med. Univ., Salzburg, Austria; zOrthopedics,
Clinical Sci. Lund, Lund Univ., Lund, Sweden
Purpose: An ACL tear is a common knee injury, involving a serious
trauma and a subsequent period of chronic alterations in joint biome-
chanics. The risk of developing incident knee OA after an ACL tear is
known to be highly elevated although the driving mechanisms are not
known. In this study, we tested the hypothesis that treatment of the
initial injury inﬂuenced change in femorotibial cartilage thickness over
the ﬁrst ﬁve years after injury. We thus explored femorotibial cartilage
thickness changes during the ﬁrst 2 years (BL/Y2) and during
a subsequent three-year period (Y2/Y5) after an acute ACL tear.
